ARTICLE | Management Tracks
CEO Christi Shaw leaving Gilead’s Kite
Plus: MorphoSys’ Lee named CFO at Vir, and updates from Novo Nordisk, PathAI, PhRMA and NORD
February 18, 2023 1:12 AM UTC
Christi Shaw will step down as CEO of Kite Pharma, a Gilead Sciences Inc. (NASDAQ:GILD) company, at the end of March. Shaw became the CEO in 2019, before which she held roles at Eli Lilly and Co. (NYSE:LLY), Novartis AG (SIX:NOVN; NYSE:NVS) and Johnson & Johnson (NYSE:JNJ). A search for her successor has begun.
Immunological disease company Vir Biotechnology Inc. (NASDAQ:VIR) hired Sung Lee as EVP and CFO, effective March 27. Lee, a 14-year veteran of Gilead, was CFO at MorphoSys AG (NASDAQ:MOR; Xetra:MOR) and Sangamo Therapeutics Inc. (NASDAQ:SGMO). He succeeds Howard Horn, who has resigned and will remain in an advisory role through a transition period. ...